Fatigue in multiple sclerosis: Mechanisms and management

Clinical Neurophysiology

Volumn 121, Issue 6, 2010, Pages 809-817

  Vucic, Steve ^a,b   Burke, David ^c   Kiernan, Matthew C ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Conduction failure; Fatigue; Multiple sclerosis

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMANTADINE; MODAFINIL; OLIVE OIL; PEMOLINE; POTASSIUM CHANNEL; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL;

ABDOMINAL PAIN; AEROBIC EXERCISE; ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; DIET SUPPLEMENTATION; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LIVER TOXICITY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYELINATED NERVE; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE CONDUCTION; NERVE FIBER; PARESTHESIA; PRIORITY JOURNAL; QUESTIONNAIRE; RANVIER NODE; REVIEW; SEIZURE; SELF REPORT;

FATIGUE; HUMANS; MULTIPLE SCLEROSIS; MUSCLE, SKELETAL; NEURAL CONDUCTION; NEURONS; QUESTIONNAIRES;

EID: 77952426002     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinph.2009.12.013     Document Type: Review

References (133)

1. + channel blockade impairs remyelination in the cuprizone model. Glia 48 (2004) 156-165
2. Baker M., Bostock H., Grafe P., and Martius P. Function and distribution of three types of rectifying channel in rat spinal root myelinated axons. J Physiol (Lond) 383 (1987) 45-67
3. + currents in sensory neurons. J Neurophysiol 80 (1998) 2538-2549
4. Baker M.D., and Bostock H. The pH dependence of late sodium current in large sensory neurons. Neuroscience 92 (1999) 1119-1130
5. Bakshi R., Miletich R.S., Henschel K., Shaikh Z.A., Janardhan V., Wasay M., et al. Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology 53 (1999) 1151-1153
6. Bechtold D.A., Kapoor R., and Smith K.J. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55 (2004) 607-616
7. Bechtold D.A., and Smith K.J. Sodium-mediated axonal degeneration in inflammatory demyelinating disease. J Neurol Sci 233 (2005) 27-35
8. Beenakker E.A., Oparina T.I., Hartgring A., Teelken A., Arutjunyan A.V., and De Keyser J. Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production. Neurology 57 (2001) 892-894
9. Bever Jr. C.T., Anderson P.A., Leslie J., Panitch H.S., Dhib-Jalbut S., Khan O.A., et al. Treatment with oral 3,4-diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47 (1996) 1457-1462
10. Bever Jr. C.T., Leslie J., Camenga D.L., Panitch H.S., and Johnson K.P. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann Neurol 27 (1990) 421-427
11. Bever Jr. C.T., Young D., Anderson P.A., Krumholz A., Conway K., Leslie J., et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44 (1994) 1054-1059
12. Black J.A., Liu S., Carrithers M., Carrithers L.M., and Waxman S.G. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 62 (2007) 21-33
13. Black J.A., Liu S., Hains B.C., Saab C.Y., and Waxman S.G. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 129 (2006) 3196-3208
14. Black J.A., and Waxman S.G. Phenytoin protects central axons in experimental autoimmune encephalomyelitis. J Neurol Sci 274 (2008) 57-63
15. Bolanos J.P., Almeida A., Stewart V., Peuchen S., Land J.M., Clark J.B., et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J Neurochem 68 (1997) 2227-2240
16. Boniface S.J., and Mills K.R. Suppression of motor neuron firing by transcranial magnetic stimulation in a patient with multiple sclerosis. J Neurol Neurosurg Psychiatry 55 (1992) 738-739
17. Bostock H. The strength-duration relationship for excitation of myelinated nerve: computed dependence on membrane parameters. J Physiol (Lond) 341 (1983) 59-74
18. Bostock H., and Grafe P. Activity-dependent excitability changes in normal and demyelinated rat spinal root axons. J Physiol (Lond) 365 (1985) 239-257
19. Bostock H., Sears T.A., and Sherratt R.M. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol 313 (1981) 301-315
20. + currents is compatible with modal-gating hypothesis for sodium channels. J Neurophysiol 71 (1994) 2562-2565
21. Burke D., and Jankelowitz S.K. Fatigue in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 39 (2009) 713-714
22. Burke D., Kiernan M.C., and Bostock H. Excitability of human axons. Clin Neurophysiol 112 (2001) 1575-1585
23. Burke D., Mogyoros I., Vagg R., and Kiernan M.C. Temperature dependence of excitability indices of human cutaneous afferents. Muscle Nerve 22 (1999) 51-60
24. Caldwell J.H., Schaller K.L., Lasher R.S., Peles E., and Levinson S.R. Sodium channel Na(v)1.6 is localized at nodes of ranvier, dendrites, and synapses. Proc Natl Acad Sci USA 97 (2000) 5616-5620
25. Cappelen-Smith C., Kuwabara S., Lin C.S., Mogyoros I., and Burke D. Activity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 48 (2000) 826-832
26. Cappelen-Smith C., Lin C.S., and Burke D. Activity-dependent hyperpolarization and impulse conduction in motor axons in patients with carpal tunnel syndrome. Brain 126 (2003) 1001-1008
27. Catterall W.A. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26 (2000) 13-25
28. Catterall W.A., Goldin A.L., and Waxman S.G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57 (2005) 397-409
29. Chiu S.Y., Ritchie J.M., Rogart R.B., and Stagg D. A quantitative description of membrane currents in rabbit myelinated nerve. J Physiol (Lond) 292 (1979) 149-166
30. Cohen R.A., and Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 46 (1989) 676-680
31. Colombo B., Martinelli Boneschi F., Rossi P., Rovaris M., Maderna L., Filippi M., et al. MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. J Neurol 247 (2000) 506-509
32. Craner M.J., Hains B.C., Lo A.C., Black J.A., and Waxman S.G. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 127 (2004) 294-303
33. de Saint Hilaire Z., Orosco M., Rouch C., Blanc G., and Nicolaidis S. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 12 (2001) 3533-3537
34. Di Fabio R.P., Choi T., Soderberg J., and Hansen C.R. Health-related quality of life for patients with progressive multiple sclerosis: influence of rehabilitation. Phys Ther 77 (1997) 1704-1716
35. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59 (2006) 478-489
36. Filippi M., Rocca M.A., Colombo B., Falini A., Codella M., Scotti G., et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. NeuroImage 15 (2002) 559-567
37. Fisk J.D., Pontefract A., Ritvo P.G., Archibald C.J., and Murray T.J. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 21 (1994) 9-14
38. Flensner G., Ek A.C., and Soderhamn O. Reliability and validity of the Swedish version of the Fatigue Impact Scale (FIS). Scand J Occup Ther 12 (2005) 170-180
39. Freal J.E., Kraft G.H., and Coryell J.K. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 65 (1984) 135-138
40. French C.R., Sah P., Buckett K.J., and Gage P.W. A voltage-dependent persistent sodium current in mammalian hippocampal neurons. J Gen Physiol 95 (1990) 1139-1157
41. Gandevia S.C. Spinal and supraspinal factors in human muscle fatigue. Physiol Rev 81 (2001) 1725-1789
42. Goodman A.D., Brown T.R., Krupp L.B., Schapiro R.T., Schwid S.R., Cohen R., et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373 (2009) 732-738
43. Grafe P., Bostock H., and Schneider U. The effects of hyperglycaemic hypoxia on rectification in rat dorsal root axons. J Physiol 480 (1994) 297-307
44. Hayes K.C., Hull T.C., Delaney G.A., Potter P.J., Sequeira K.A., Campbell K., et al. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma 19 (2002) 753-761
45. Inglese M., Park S.J., Johnson G., Babb J.S., Miles L., Jaggi H., et al. Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch Neurol 64 (2007) 196-202
46. Iriarte J., Katsamakis G., and de Castro P. The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Mult Scler 5 (1999) 10-16
47. Jonas P., Brau M.E., Hermsteiner M., and Vogel W. Single-channel recording in myelinated nerve fibers reveals one type of Na channel but different K channels. Proc Natl Acad Sci USA 86 (1989) 7238-7242
48. Judge S.I., and Bever Jr. C.T. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 111 (2006) 224-259
49. Kaji R. Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies. Muscle Nerve 27 (2003) 285-296
50. Kaji R., Bostock H., Kohara N., Murase N., Kimura J., and Shibasaki H. Activity-dependent conduction block in multifocal motor neuropathy. Brain 123 (2000) 1602-1611
51. Kaji R., and Sumner A.J. Ouabain reverses conduction disturbances in single demyelinated nerve fibers. Neurology 39 (1989) 1364-1368
52. Kiernan M.C., Lin C.S., and Burke D. Differences in activity-dependent hyperpolarization in human sensory and motor axons. J Physiol (Lond) 558 (2004) 341-349
53. Koester J. Membrane potential. In: Kandel E., Schwartz E., and Jessel T. (Eds). Principles of neural science (1991), Elsevier, New York 81-94
54. Kos D., Kerckhofs E., Nagels G., D'Hooghe M.B., and Ilsbroukx S. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair 22 (2008) 91-100
55. Kos D., Nagels G., D'Hooghe M.B., Duportail M., and Kerckhofs E. A rapid screening tool for fatigue impact in multiple sclerosis. BMC Neurol 6 (2006) 27
56. Krupp L.B., Alvarez L.A., LaRocca N.G., and Scheinberg L.C. Fatigue in multiple sclerosis. Arch Neurol 45 (1988) 435-437
57. Krupp L.B., Coyle P.K., Doscher C., Miller A., Cross A.H., Jandorf L., et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 45 (1995) 1956-1961
58. Krupp L.B., LaRocca N.G., Muir-Nash J., and Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46 (1989) 1121-1123
59. Lee M., Gandevia S., and Carroll T. Cortical voluntary activation can be reliably measured in human wrist extensors using transcranial magnetic stimulation. Clin Neurophysiol 119 (2008) 1130-1138
60. Leocani L., Colombo B., Magnani G., Martinelli-Boneschi F., Cursi M., Rossi P., et al. Fatigue in multiple sclerosis is associated with abnormal cortical activation to voluntary movement - EEG evidence. Neuroimage 13 (2001) 1186-1192
61. Liepert J., Mingers D., Heesen C., Baumer T., and Weiller C. Motor cortex excitability and fatigue in multiple sclerosis: a transcranial magnetic stimulation study. Mult Scler 11 (2005) 316-321
62. Lloyd A.R., Gandevia S.C., and Hales J.P. Muscle performance, voluntary activation, twitch properties and perceived effort in normal subjects and patients with the chronic fatigue syndrome. Brain 114 (1991) 85-98
63. Loo C., Sachdev P., Mitchell P., Gandevia S., Malhi G., Todd G., et al. A study using transcranial magnetic stimulation to investigate motor mechanisms in psychomotor retardation in depression. Int J Neuropsychop 11 (2008) 935-946
64. Lo A.C., Saab C.Y., Black J.A., and Waxman S.G. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90 (2003) 3566-3571
65. Mahad D., Ziabreva I., Lassmann H., and Turnbull D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 131 (2008) 1722-1735
66. Mainero C., Faroni J., Gasperini C., Filippi M., Giugni E., Ciccarelli O., et al. Fatigue and magnetic resonance imaging activity in multiple sclerosis. J Neurol 246 (1999) 454-458
67. Marrie R.A., Fisher E., Miller D.M., Lee J.C., and Rudick R.A. Association of fatigue and brain atrophy in multiple sclerosis. J Neurol Sci 228 (2005) 161-166
68. Mathiowetz V. Test-retest reliability and convergent validity of the Fatigue Impact Scale for persons with multiple sclerosis. Am J Occup Ther 57 (2003) 389-395
69. McDonald W.I., and Sears T.A. The effects of experimental demyelination on conduction in the central nervous system. Brain 93 (1970) 583-598
70. Murray T.J. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 12 (1985) 251-254
71. Nielsen J.F., and Norgaard P. Increased post-exercise facilitation of motor evoked potentials in multiple sclerosis. Clin Neurophysiol 113 (2002) 1295-1300
72. Niepel G., Tench Ch.R., Morgan P.S., Evangelou N., Auer D.P., and Constantinescu C.S. Deep gray matter and fatigue in MS: a T1 relaxation time study. J Neurol 253 (2006) 896-902
73. Nodera H., Bostock H., Izumi Y., Nakamura K., Urushihara R., Sakamoto T., et al. Activity-dependent conduction block in multifocal motor neuropathy: magnetic fatigue test. Neurology 67 (2006) 280-287
74. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N Engl J Med 343 (2000) 938-952
75. Patti F., Ciancio M.R., Reggio E., Lopes R., Palermo F., Cacopardo M., et al. The impact of outpatient rehabilitation on quality of life in multiple sclerosis. J Neurol 249 (2002) 1027-1033
76. Perretti A., Balbi P., Orefice G., Trojano L., Marcantonio L., Brescia-Morra V., et al. Post-exercise facilitation and depression of motor evoked potentials to transcranial magnetic stimulation: a study in multiple sclerosis. Clin Neurophysiol 115 (2004) 2128-2133
77. Polman C.H., Bertelsmann F.W., de Waal R., van Diemen H.A., Uitdehaag B.M., van Loenen A.C., et al. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 51 (1994) 1136-1139
78. Polman C.H., Bertelsmann F.W., van Loenen A.C., and Koetsier J.C. 4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 51 (1994) 292-296
79. Rakowski R.F., Gadsby D.C., and De Weer P. Stoichiometry and voltage dependence of the sodium pump in voltage-clamped, internally dialyzed squid giant axon. J Gen Physiol 93 (1989) 903-941
80. Rammohan K.W., Rosenberg J.H., Lynn D.J., Blumenfeld A.M., Pollak C.P., and Nagaraja H.N. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72 (2002) 179-183
81. Rasband M.N., Trimmer J.S., Schwarz T.L., Levinson S.R., Ellisman M.H., Schachner M., et al. Potassium channel distribution, clustering, and function in remyelinating rat axons. J Neurosci 18 (1998) 36-47
82. Rasminsky M. The effects of temperature on conduction in demyelinated single nerve fibers. Arch Neurol 28 (1973) 287-292
83. Rasova K., Brandejsky P., Havrdova E., Zalisova M., and Rexova P. Spiroergometric and spirometric parameters in patients with multiple sclerosis: are there any links between these parameters and fatigue, depression, neurological impairment, disability, handicap and quality of life in multiple sclerosis?. Mult Scler 11 (2005) 213-221
84. Rasova K., Havrdova E., Brandejsky P., Zalisova M., Foubikova B., and Martinkova P. Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiple sclerosis. Mult Scler 12 (2006) 227-234
85. Reddy H., Narayanan S., Arnoutelis R., Jenkinson M., Antel J., Matthews P.M., et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain 123 (2000) 2314-2320
86. Redford E.J., Kapoor R., and Smith K.J. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 120 (1997) 2149-2157
87. Reid G., Scholz A., Bostock H., and Vogel W. Human axons contain at least five types of voltage-dependent potassium channel. J Physiol (Lond) 518 (1999) 681-696
88. Ritchie J.M., and Rogart R.B. The binding of saxitoxin and tetrodotoxin to excitable tissue. Rev Physiol Biochem Pharmacol 79 (1977) 1-50
89. Rocca M.A., Matthews P.M., Caputo D., Ghezzi A., Falini A., Scotti G., et al. Evidence for widespread movement-associated functional MRI changes in patients with PPMS. Neurology 58 (2002) 866-872
90. 18F-fluorodeoxyglucose positron emission tomography study. Neurology 48 (1997) 1566-1571
91. Romberg A., Virtanen A., Ruutiainen J., Aunola S., Karppi S.L., Vaara M., et al. Effects of a 6-month exercise program on patients with multiple sclerosis: a randomized study. Neurology 63 (2004) 2034-2038
92. Rosenberg G.A., and Appenzeller O. Amantadine, fatigue, and multiple sclerosis. Arch Neurol 45 (1988) 1104-1106
93. Rossini P.M., Pasqualetti P., Pozzilli C., Grasso M.G., Millefiorini E., Graceffa A., et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 7 (2001) 354-358
94. + channels and their functions in small dorsal root ganglion neurones of rat. J Physiol (Lond) 493 (1996) 393-408
95. Scholz A., Reid G., Vogel W., and Bostock H. Ion channels in human axons. J Neurophysiol 70 (1993) 1274-1279
96. Schwarz J.R., Reid G., and Bostock H. Action potentials and membrane currents in the human node of Ranvier. Pflugers Arch 430 (1995) 283-292
97. Schwid S.R., Petrie M.D., Murray R., Leitch J., Bowen J., Alquist A., et al. A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology 60 (2003) 1955-1960
98. Sheean G.L., Murray N.M., Rothwell J.C., Miller D.H., and Thompson A.J. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 120 (1997) 299-315
99. Sheean G.L., Murray N.M., Rothwell J.C., Miller D.H., and Thompson A.J. An open-labelled clinical and electrophysiological study of 3,4-diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 121 (1998) 967-975
100. Shrager P., Custer A.W., Kazarinova K., Rasband M.N., and Mattson D. Nerve conduction block by nitric oxide that is mediated by the axonal environment. J Neurophysiol 79 (1998) 529-536
101. Smith K., Kapoor R., and Felts P. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9 (1999) 69-92
102. Smith K.J. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol 17 (2007) 230-242
103. Stankoff B., Waubant E., Confavreux C., Edan G., Debouverie M., Rumbach L., et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 64 (2005) 1139-1143
104. Storr L.K., Sorensen P.S., and Ravnborg M. The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. Mult Scler 12 (2006) 235-242
105. Stys P.K. General mechanisms of axonal damage and its prevention. J Neurol Sci 233 (2005) 3-13
106. Surakka J., Romberg A., Ruutiainen J., Aunola S., Virtanen A., Karppi S.L., et al. Effects of aerobic and strength exercise on motor fatigue in men and women with multiple sclerosis: a randomized controlled trial. Clin Rehabil 18 (2004) 737-746
107. Tasaki I. Conduction of the nerve impulse. In: Field J. (Ed). Handbook of physiology, section 1, neurophysiology (1959), American Physiological Society, Washington, DC 75-121
108. Tedeschi G., Dinacci D., Lavorgna L., Prinster A., Savettieri G., Quattrone A., et al. Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. J Neurol Sci 263 (2007) 15-19
109. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 14 (1987) 273-278
110. Thickbroom G.W., Sacco P., Faulkner D.L., Kermode A.G., and Mastaglia F.L. Enhanced corticomotor excitability with dynamic fatiguing exercise of the lower limb in multiple sclerosis. J Neurol 255 (2008) 1001-1005
111. Thickbroom G.W., Sacco P., Kermode A.G., Archer S.A., Byrnes M.L., Guilfoyle A., et al. Central motor drive and perception of effort during fatigue in multiple sclerosis. J Neurol 253 (2006) 1048-1053
112. Thomas R.C. Electrogenic sodium pump in nerve and muscle cells. Physiol Rev 52 (1972) 563-594
113. Tomassini V., Pozzilli C., Onesti E., Pasqualetti P., Marinelli F., Pisani A., et al. Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 218 (2004) 103-108
114. US Food and Drug Administration. FDA Approval Decisions Report for September, 2009. Available from: http://www.reveredata.com/reports/store/report/fda/FDA200909.
115. Vagg R., Mogyoros I., Kiernan M.C., and Burke D. Activity-dependent hyperpolarization of human motor axons produced by natural activity. J Physiol (Lond) 507 (1998) 919-925
116. van der Kamp W., Maertens de Noordhout A., Thompson P.D., Rothwell J.C., Day B.L., and Marsden C.D. Correlation of phasic muscle strength and corticomotoneuron conduction time in multiple sclerosis. Ann Neurol 29 (1991) 6-12
117. van der Werf S.P., Jongen P.J., Lycklama a Nijeholt G.J., Barkhof F., Hommes O.R., and Bleijenberg G. Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability. J Neurol Sci 160 (1998) 164-170
118. van Diemen H.A., Polman C.H., van Dongen T.M., van Loenen A.C., Nauta J.J., Taphoorn M.J., et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 32 (1992) 123-130
119. Watson B.V., Brown W.F., and Doherty T.J. Frequency-dependent conduction block in carpal tunnel syndrome. Muscle Nerve 33 (2006) 619-626
120. Waxman S. Demyelinating diseases - new pathological insights, new therapeutic targets. N Engl J Med 338 (1998) 323-325
121. Waxman S.G. Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 306 (1982) 1529-1533
122. Waxman S.G. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci 7 (2006) 932-941
123. Waxman S.G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat Clin Pract Neurol 4 (2008) 159-169
124. Waxman S.G., and Ritchie J.M. Molecular dissection of the myelinated axon. Ann Neurol 33 (1993) 121-136
125. Weinshenker B.G., Penman M., Bass B., Ebers G.C., and Rice G.P. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 42 (1992) 1468-1471
126. Weinstock-Guttman B., Baier M., Park Y., Feichter J., Lee-Kwen P., Gallagher E., et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 397-404
127. + ATPase in chronic multiple sclerosis lesions. Ann Neurol 63 (2008) 428-435
128. Yu F.H., Yarov-Yarovoy V., Gutman G.A., and Catterall W.A. Overview of molecular relationships in the voltage-gated ion channel superfamily. Pharmacol Rev 57 (2005) 387-395
129. Ziemann U. Pharmacology of TMS. Clin Neurophysiol 56 (2003) 226-231
130. Ziemann U. Cortical threshold and excitability measurements. In: Eisen A. (Ed). Clinical neurophysiology of motor neuron diseases handbook of clinical neurophysiology (2004), Elsevier, Amsterdam 317-335
131. Ziemann U. TMS and drugs. Clin Neurophysiol 115 (2004) 1717-1729
132. Zifko U.A., Rupp M., Schwarz S., Zipko H.T., and Maida E.M. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 249 (2002) 983-987
133. Zwarts M.J., Bleijenberg G., and van Engelen B.G. Clinical neurophysiology of fatigue. Clin Neurophysiol 119 (2008) 2-10